Evolent Health, Inc. (NYSE:EVH) President Daniel Joseph Mccarthy Sells 11,000 Shares of Stock

Evolent Health, Inc. (NYSE:EVH) President Daniel Joseph Mccarthy sold 11,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $30.00, for a total transaction of $330,000.00. Following the transaction, the president now directly owns 198,333 shares of the company’s stock, valued at approximately $5,949,990. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Evolent Health Price Performance

Shares of NYSE EVH opened at $29.16 on Tuesday. The stock’s 50-day moving average is $26.92 and its two-hundred day moving average is $28.61. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market cap of $3.35 billion, a price-to-earnings ratio of -28.59 and a beta of 1.44. Evolent Health, Inc. has a 1-year low of $23.33 and a 1-year high of $36.70.

Institutional Trading of Evolent Health

Large investors have recently made changes to their positions in the company. FMR LLC grew its holdings in Evolent Health by 214.2% during the 1st quarter. FMR LLC now owns 14,641,699 shares of the technology company’s stock worth $461,373,000 after acquiring an additional 9,980,971 shares in the last quarter. RA Capital Management L.P. purchased a new position in Evolent Health in the third quarter valued at $74,520,000. William Blair Investment Management LLC acquired a new stake in Evolent Health in the second quarter valued at $80,930,000. Bellevue Group AG lifted its holdings in Evolent Health by 57.4% during the 2nd quarter. Bellevue Group AG now owns 3,448,322 shares of the technology company’s stock worth $104,484,000 after buying an additional 1,257,175 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Evolent Health by 90.8% during the 1st quarter. Wellington Management Group LLP now owns 2,499,435 shares of the technology company’s stock worth $81,107,000 after acquiring an additional 1,189,594 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on EVH shares. UBS Group began coverage on shares of Evolent Health in a research report on Monday, October 16th. They set a “buy” rating and a $46.00 price objective for the company. Guggenheim restated a “buy” rating and set a $47.00 price target on shares of Evolent Health in a research report on Monday, August 14th. Truist Financial cut their price objective on Evolent Health from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 14th. StockNews.com upgraded Evolent Health to a “sell” rating in a report on Monday, October 16th. Finally, Wedbush reiterated an “outperform” rating on shares of Evolent Health in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Evolent Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.75.

Evolent Health Company Profile

Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.